Aardvark Therapeutics reports lower-than-expected 2025 net loss

Reuters03-24
<a href="https://laohu8.com/S/AARD">Aardvark Therapeutics</a> reports lower-than-expected 2025 net loss

Overview

  • US biopharmaceutical firm's 2025 net loss slightly beat analyst expectations

Outlook

  • Aardvark expects to provide further guidance on ARD-101 and ARD-201 programs in Q2 2026

  • Company's cash position supports projected operations into Q2 2027

Result Drivers

  • R&D SPENDING - Higher research and development expenses driven by increased external costs for ARD-101 and personnel-related expenses

  • G&A EXPENSES - General and administrative expenses rose due to higher personnel, legal, and professional services costs

Company press release: ID:nGNX6slMSw

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Net Income

Slight Beat*

-$57.59 mln

-$58.16 mln (12 Analysts)

FY Income from Operations

-$62.7 mln

FY Operating Expenses

$62.7 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Aardvark Therapeutics Inc is $21.00, about 416% above its March 20 closing price of $4.07

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment